Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer.

doi:10.1158/1078-0432.CCR-24-3660

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2025

Zhang Le, Teng Pai-Chi, Cavassani Karen A, Wang Jasmine, Grasso Catherine, Watson Joshua, Chen Zijing, Tu Kai-Han, Salumbides Brenda, Rohena-Rivera Krizia, Gevorkian Lilit, Kim Minhyung, You Sungyong, Di Vizio Dolores, Sandler Howard M, Daskivich Timothy, Bhowmick Neil A, Freeman Michael R, Tseng Hsian-Rong, Chen Jie-Fu, Posadas Edwin M

Abstract excerpt

PURPOSE: Circulating tumor cells (CTC) with a very-small-nuclear phenotype (vsnCTC) in prostate cancer are characterized by nuclei smaller than 8.5 μm. Our previous studies established an association between vsnCTCs and visceral metastasis. Reduction of emerin (EMD), a nuclear envelope protein, contributes to prostate cancer metastasis and nuclear shape instability. In this study, we investigated the correlation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Lineage

Share to Cell Nucleus

Share to Drug Resistance, Neoplasm

Share to Neoplastic Cells, Circulating

Share to Nitriles

Share to Prostatic Neoplasms

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 40063516
DOI: 10.1158/1078-0432.CCR-24-3660
PMCID: PMC12079098

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer.PMID 40063516Read ↗

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerSemantic proximity Read ↗

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerSemantic proximity Read ↗

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approachesSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

The Role of Emerin in Cancer Progression and Metastasis.Semantic proximity Read ↗

Polyploid cancer cells reveal signatures of chemotherapy resistanceSemantic proximity Read ↗

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancersSemantic proximity Read ↗

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Polyploid cancer cells reveal signatures of chemotherapy resistanceSemantic proximity Read ↗

Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.